(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 24 February 2005 (24.02.2005)

PCT

(10) International Publication Number WO 2005/017185 A2

(51) International Patent Classification7:

C12Q

(21) International Application Number:

PCT/US2004/022907

(22) International Filing Date:

16 July 2004 (16.07.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/488,237

16 July 2003 (16.07.2003)

- (71) Applicant (for all designated States except US): LIGAND PHARMCEUTICALS INCORPORATED [US/US]; 10275 Science Center Drive, San Diego, CA 92121 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MICHELLYS, Pierre [FR/US]; 10824 Poblado Road, #221, San Diego. CA 92127 (US). CHEN, Jyun-Hung [—/US]; 7614 Palmilla Drive, #58, San Diego, CA 92122 (US). MAPES, Christopher [US/US]; 8255 Pasadena Avenue, La Mesa, CA 91941 (US). RUPPAR, Daniel [US/US]; 5230 Fiore Terrace #K-404, San Diego, CA 92122 (US). KARANEWSKY, Donald [US/US]; 1797 Continental Lane, Escondido, CA 92029 (US). THOMPSON, Anthony [US/US]; 1000 Escalon Avenue, #1045, Sunnyvale, CA 94085 (US).

- (74) Agents: SEIDMAN, Stephanie, L. et al.; Fish & Richardson P.C., 12390 El Camino Real, San Diego, CA 92130 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS

(57) Abstract: The present invention is directed to hepatocyte nuclear factor 4α (HNF- 4α) receptor modulator compounds. This invention is also directed to pharmaceutical compositions containing such compounds as well as methods of using such compounds and pharmaceutical compositions for modulating HNF-4 α receptors as well as processes mediated by HNF-4 α receptors. Also provided are methods of making such compounds and pharmaceutical compositions, as well as intermediates used in their synthesis.



(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 24 February 2005 (24.02.2005)

PCT

(10) International Publication Number WO 2005/017185 A3

- (51) International Patent Classification7: A61K 31/47, 31/385, 31/35, 31/075, C07D 311/04, 335/04, 215/00, 215/16, C07C 41/00
- (21) International Application Number:

PCT/US2004/022907

- (22) International Filing Date: 16 July 2004 (16.07.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/488,237

16 July 2003 (16.07.2003) US

- (71) Applicant (for all designated States except US): LIGAND PHARMCEUTICALS INCORPORATED [US/US]; 10275 Science Center Drive, San Diego, CA 92121 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MICHELLYS, Pierre [FR/US]; 10824 Poblado Road, #221, San Diego, CA 92127 (US). CHEN, Jyun-Hung [-/US]; 7614 Palmilla Drive, #58, San Diego, CA 92122 (US). MAPES, Christopher [US/US]; 8255 Pasadena Avenue, La Mesa, CA 91941 (US). RUPPAR, Daniel [US/US]; 5230 Fiore Terrace #K-404, San Diego, CA 92122 (US). KARANEWSKY, Donald [US/US]; 1797 Continental Lane, Escondido, CA 92029 (US). THOMPSON, Anthony [US/US]; 1000 Escalon Avenue, #1045, Sunnyvale, CA 94085 (US).

- (74) Agents: SEIDMAN, Stephanie, L. et al.; Fish & Richardson P.C., 12390 El Camino Real, San Diego, CA 92130 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 14 July 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS

(57) Abstract: The present invention is directed to hepatocyte nuclear factor 4α (HNF-4α) receptor modulator compounds. This invention is also directed to pharmaceutical compositions containing such compounds as well as methods of using such compounds and pharmaceutical compositions for modulating HNF-4α receptors as well as processes mediated by HNF-4α receptors. Also provided are methods of making such compounds and pharmaceutical compositions, as well as intermediates used in their synthesis.